Zika virus could help combat brain cancer

Zika virus, known for causing microcephaly in babies by attacking the cells that give rise to the fetus's cerebral cortex, could be an alternative for treatment of glioblastoma, the most common and aggressive malignant brain ...

Feb 22, 2018
popularity58 comments 0

Insights into how brain cancer evades the immune system

Glioblastoma—a universally fatal form of brain cancer—is known for its ability to hijack immune checkpoints and evade detection and destruction by the body's immune defenses. But many of the details underlying this feat ...

Mar 07, 2018
popularity81 comments 0

Breaking the rules of brain cancer

A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

Feb 14, 2018
popularity66 comments 0

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

How do we lose memory? A STEP at a time, researchers say

In mice, rats, monkeys, and people, aging can take its toll on cognitive function. A new study by researchers at Yale and Université de Montréal reveal there is a common denominator to the decline in all of these species—an ...